Alzamend Neuro, Inc. (ALZN): Price Target Chart
Alzamend Neuro, Inc. (ALZN) is developing cutting-edge immunotherapy methods to combat Alzheimer's disease, leveraging investment capital to conduct brain research. The current financial metric stands at 26.08, with business success directly tied to the results of early-stage testing. A diverse pipeline of psychiatric and cellular technology developments minimizes risks. This chart illustrates the company's share price action.
Analytical breakdowns for Alzamend Neuro, Inc. (ALZN)
- stock value and consensus price forecast:
- stock exchange capitalization data:
- issuer book value statistics:
- business debt structure and liquidity details:
Debt to Equity Ratio Alzamend Neuro, Inc.|ALZN - Long-Term Debt to Capital|Current Liabilities to Capital alzamend.com|ALZN - Company Total Debt|Debts to Book Capitalization Alzamend|ALZN - Company Long-Term Debt|Company Short-Term Loans and Borrowings Alzamend Neuro|Immediate Liquidity alzamend.com
- earnings and valuation multiples indicators:
ALZN - Net Profit|Projected Future Earnings Alzamend Neuro, Inc.|ALZN - Price to Earnings Ratio|Future Price to Earnings alzamend.com|ALZN - Price/Earnings to Growth Multiple|Company Value to Operating Income Before Depreciation Ratio Alzamend|ALZN - Operating profit EBITDA|Net earnings per share (EPS TTM) Alzamend Neuro|ALZN - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months alzamend.com|ALZN - Earnings growth in current year|Expected net earnings per share growth next year Alzamend Neuro, Inc.
Summary company analytics:ALZN Alzamend Neuro Inc.
Alzamend Neuro, Inc. (ALZN) development of the innovative LiPRO system for the safe therapy of Alzheimer's disease creates high uncertainty regarding the asset's value. By analyzing the history of the consensus price target for the stock, an investor assesses the degree of smoothing in aggregated analyst forecasts, which allows for the differentiation of speculative volatility from the fundamental maturity of the business and determines the risk of capital freeze in a low-liquidity asset.
Competitors of Alzamend Neuro, Inc.
Analyst Consensus Forecast biogen.com (BIIB)|Price Target Chart Neurocrine Biosciences, Inc. NBIX|Regencell Bioscience Ltd - Price Target Chart|AXSM: Consensus Target|Forecast Levels Chart ACAD|Xenon Pharmaceuticals (XENE) - Price Target Chart|Broker Consensus Forecast VKTX|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|PRTA (Prothena Corporation PLC) - Analyst Consensus Forecast|Analyst Consensus Forecast Alector Therapeutics|Price Target Chart Annexon (ANNX)|Price Target Chart OMER (omeros.com)|Neurogene Corp - Consensus Target|ACIU (AC Immune Inc) - Forecast Levels Chart|Voyager Therapeutics - Analyst Consensus Forecast|NMRA - Analyst Consensus Forecast|Scilex (SCLX) - Price Target Chart|Consensus Target Tevogen Bio Holdings Inc.|ACOG (Alpha Cognition Inc) - Analyst Consensus Forecast|Average Forecast Price cogrx.com CGTX|Price Target Chart Inhibikase Therapeutics (IKT)|cassavasciences.com - Broker Consensus Forecast|Analyst Consensus Forecast ASRT (Assertio)|COYA: Broker Consensus Forecast|VTGN: Consensus Target|Fair Value Consensus OVID (Ovid Therapeutics Inc.)|Acumen Pharmaceuticals (ABOS) - Price Target Chart|Broker Consensus Forecast CRVO|ATHE (Alterity Therapeutics Ltd.) - Analyst Consensus Forecast|Average Forecast Price Clene Nanomedicine CLNN|Consensus Target PEPG (PepGen Inc.)|Analyst Consensus Forecast jupiterneurosciences.com (JUNS)|Price Target Chart Relmada Therapeutics RLMD|Fair Value Consensus ANVS|GRCE - Price Target Chart|Average Forecast Price Firefly Neuroscience, Inc.|KLTO (anewmeds.com) - Consensus Target|NeuroSense Therapeutics Ltd. - Fair Value Consensus|RVPH (Reviva Pharmaceuticals) - Analyst Consensus Forecast|MetaVia, Inc. (MTVA) - Analyst Median Target|Price Target Chart NeurAxis (NRXS)|heliusmedical.com - Broker Consensus Forecast|Analyst Consensus Forecast PASG (Passage Bio)|NEUP - Consensus Target|NERV: Consensus Target|Analyst Median Target athira.com ATHA|ADXN: Analyst Consensus Forecast|Cyclerion Therapeutics, Inc. (CYCN) - Analyst Consensus Forecast|Price Target Chart Protagenic Therapeutics Inc.|Price Target Chart KTTA|Consensus Target CRGT (Cortigent, Inc.)|ATXI: Forecast Levels Chart|Price Target Chart BrainStorm Cell Therapeutics BCLI|CARA: Broker Consensus Forecast|CHRO - Price Target Chart|ELYM (Eliem Therapeutics) - Broker Consensus Forecast|ITCI: Analyst Consensus Forecast|Average Forecast Price longboardpharma.com (LBPH)|Consensus Target MRNS|Analyst Consensus Forecast NKGen Biotech Inc|Price Target Chart NeuroBo (NRBO)|SAGE (Sage Therapeutics Inc) - Fair Value Consensus|Price Target Chart Synaptogenix, Inc. SNPX|trevena.com (TRVN) - Average Forecast Price|Vigil Neuro - Analyst Consensus Forecast|WENA - Analyst Consensus Forecast|Cerevel (CERE) - Price Target Chart
